Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Warner Lambert Co LLC | 26 |
| 2 | Cincinnati Children's Hospital Medical Center | 19 |
| 3 | University of Pittsburgh | 9 |
| 4 | University of South Florida St. Petersburg | 8 |
| 5 | Yale University | 8 |
| 6 | Massachusetts Institute of Technology | 7 |
| 7 | Alcon Research LLC | 5 |
| 8 | University of South Florida | 5 |
| 9 | Eiger Biopharmaceuticals Inc | 4 |
| 10 | Cellectis SA | 3 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 125 |
| 2 | A61K | Medicinal preparations | 118 |
| 3 | C07K | Peptides | 49 |
| 4 | C07D | Heterocyclic compounds | 36 |
| 5 | Y02A | Climate change adaptation | 19 |
| 6 | G01N | Investigating / analysing materials | 14 |
| 7 | C07C | Acyclic and carbocyclic compounds | 9 |
| 8 | C12N | Microorganisms, enzymes | 7 |
| 9 | C12Q | Measuring/testing involving enzymes | 7 |
| 10 | A23L | Foods and beverages (general) | 5 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Andrew D. Hamilton | Yale University | 7 |
| 2 | Gerry Sullivan | Abbott Fund | 2 |
| 3 | Joëlle Dubois | Institut de Chimie des Substances Naturelles | 4 |
| 4 | Junko Ohkanda | Yale University | 4 |
| 5 | Saı̈d M. Sebti | Moffitt Cancer Center | 4 |
| 6 | Badr Saeed | Abbott (United Kingdom) | 3 |
| 7 | Haichao Zhang | Abbott (United Kingdom) | 3 |
| 8 | Jeffrey W. Lockman | Yale University | 3 |
| 9 | Jerry D. Cohen | Abbott (United Kingdom) | 3 |
| 10 | Laura E. Lantry | University of Toledo Medical Center | 3 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Targeting RAS signalling pathways in cancer therapy | 2003 | 3259 | Protein Kinase Regulation and GTPase Signaling |
| Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes | 1995 | 363 | Protein Kinase Regulation and GTPase Signaling |
| Farnesyltransferase Inhibitors Potentiate the Antitumor Effect of Radiation on a Human Tumor Xenograft Expressing Activated HRAS<sup>1</sup> | 2000 | 74 | Protein Kinase Regulation and GTPase Signaling |
| Ras‐MEK‐ERK signaling cascade regulates androgen receptor element‐inducible gene transcription and DNA synthesis in prostate cancer cells | 2007 | 53 | Prostate Cancer Treatment and Research |
| Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone | 2000 | 47 | Protein Kinase Regulation and GTPase Signaling |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of FTI-276?
Which organizations hold the most patents related to FTI-276?
What is the primary research focus of publications on FTI-276?
How many patents have been filed for FTI-276 in the last three years?
What are the main patent classification codes for FTI-276 related inventions?